Xu Jiayi
The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
Health Science Center, Qingdao University, Qingdao, China.
NPJ Precis Oncol. 2025 Aug 6;9(1):275. doi: 10.1038/s41698-025-00990-x.
The TNF receptor superfamily (TNFRSF) with extracellular cysteine-rich domains, transmembrane segments, and intracellular signaling motifs, plays crucial roles in cell death, inflammation, growth, and development. These cysteine-rich domains, which are located in the external portion of the TNFRSF, can contain varying numbers of domains, from as few as 1 (as seen in BCMA) to more than 3 (as observed in CD30, DR3), and function as the primary interaction sites for their corresponding ligands from TNFSF. In cancer research, TNFRSF members show abnormal expression across various cancer types, making them potential therapeutic targets. This review focuses on TNFRSF's structure, biological functions, and significance in cancer. It explores immunotherapeutic applications, targeted drug therapies, and biomarker potential, aiming to offer new perspectives on cancer diagnostics and treatments. However, challenges remain in translating these findings into effective therapies, and further research is needed to overcome these hurdles and improve cancer prognosis.
肿瘤坏死因子受体超家族(TNFRSF)具有细胞外富含半胱氨酸的结构域、跨膜区段和细胞内信号基序,在细胞死亡、炎症、生长和发育中发挥关键作用。这些富含半胱氨酸的结构域位于TNFRSF的外部,其结构域数量各不相同,少则1个(如在BCMA中所见),多则超过3个(如在CD30、DR3中观察到的),并作为其来自肿瘤坏死因子超家族(TNFSF)的相应配体的主要相互作用位点。在癌症研究中,TNFRSF成员在各种癌症类型中均表现出异常表达,使其成为潜在的治疗靶点。本综述聚焦于TNFRSF的结构、生物学功能及其在癌症中的意义。它探讨了免疫治疗应用、靶向药物治疗以及生物标志物潜力,旨在为癌症诊断和治疗提供新的视角。然而,将这些研究结果转化为有效疗法仍面临挑战,需要进一步研究以克服这些障碍并改善癌症预后。